Clinical Trial Detail

NCT ID NCT02014909
Title A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Kolltan Pharmaceuticals, Inc.
Indications

melanoma

stomach cancer

non-small cell lung carcinoma

Her2-receptor positive breast cancer

head and neck cancer

colon cancer

Advanced Solid Tumor

Therapies

CDX-3379

CDX-3379 + Vemurafenib

CDX-3379 + Trastuzumab

CDX-3379 + Cetuximab

CDX-3379 + Erlotinib

Age Groups: adult

Additional content available in CKB BOOST